You just read:

Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

News provided by

Shionogi

Sep 25, 2017, 09:02 ET